What is Kayentis?
Since 2003, Kayentis has been instrumental in streamlining the collection of clinical trial data for both patients and research sites. The company offers a comprehensive suite of eCOA (electronic Clinical Outcome Assessment) solutions designed to support the modern clinical trial environment. This includes robust capabilities for decentralized and hybrid trials, enabling telehealth visits, and seamless integration with other applications and external devices. Kayentis's commitment to innovation ensures sponsors and CROs can navigate the complexities of clinical development with greater efficiency and simplicity.
How much funding has Kayentis raised?
Kayentis has raised a total of $25.5M across 5 funding rounds:
Series C
$6.2M
Unspecified
$1.6M
Private Equity
$3.9M
Private Equity
$8.3M
Other Financing Round
$5.4M
Series C (2007): $6.2M with participation from Seventure Partners
Unspecified (2015): $1.6M, investors not publicly disclosed
Private Equity (2016): $3.9M supported by Innovation Capital and Extens
Private Equity (2020): $8.3M featuring LBO France, Bpifrance, and Extens
Other Financing Round (2023): $5.4M backed by LBO France, Bpifrance, and Extens
Key Investors in Kayentis
Seventure Partners
Seventure Partners is an active partner of innovative companies in the fields of digital technologies and life sciences, investing in sectors including health and fintech.
LBO France
LBO France is a pioneering private equity firm with over 30 years of expertise, specializing in LBO Mid Cap, LBO Small Cap, real estate, and digital health ventures, managing approximately €2.5 billion in assets.
Bpifrance
Bpifrance finances companies at each stage of their development with credit, guarantees, and equity, supporting innovation projects and international expansion.
What's next for Kayentis?
With a significant funding history, Kayentis is well-positioned for continued expansion and technological advancement in the clinical trial technology space. The recent major strategic investment suggests a focus on scaling operations, enhancing its eCOA platform, and potentially exploring new market opportunities. The company's established expertise in supporting decentralized and hybrid trials aligns with current industry trends, indicating a strong trajectory for future growth and further capital infusion as it solidifies its role as a leader in clinical development solutions.
See full Kayentis company page
